Spinal Muscular Atrophy with Progressive Myoclonic Epilepsy (SMA-PME) is an ultra-rare, degenerative genetic disorder caused by mutations in the ASAH1 gene, which encodes the enzyme acid ceramidase.
When this enzyme is deficient, ceramides accumulate in the body — causing chronic inflammation, progressive damage to joints, nerves, and vital organs. The disease typically appears in early childhood and follows a relentlessly progressive course.
These neurodegenerative diseases progress rapidly. The child's physical condition deteriorates on both a muscular level — through the destruction of the nerve cells that control muscle movement — and a neurological level, ultimately leading to a complete loss of autonomy. Cardiac and respiratory complications emerge over time, and without treatment, result in the premature death of the child in late adolescence.
Farber disease and SMA-PME are both caused by mutations of only one gene : the ASAH1 gene — discovered in 19961 — which encodes the enzyme acid ceramidase, essential for normal cellular function.
Both conditions affect boys and girls equally. The ASAH1 gene is located on an autosome — a chromosome shared by both sexes — which means neither parent's sex influences transmission.
Both parents are healthy carriers: each carries one defective copy of the gene, but since the gene is recessive, a single defective copy is not enough to cause disease. However, when two carriers have a child, there is a 1-in-4 chance the child inherits both defective copies and develops the disease.
Both Farber disease and SMA-PME are lysosomal storage diseases. The defective ASAH1 gene prevents lysosomes — the cell's waste disposal/recycling system — from performing their essential function of breaking down cellular byproducts.
When both copies of the ASAH1 gene are defective, acid ceramidase — the enzyme normally responsible for processing ceramides (lipids found in cell membranes) — becomes severely non-functional. This leads to a toxic buildup of ceramides in most tissues, causing progressive multi-organ damage.
The degree of enzyme activity remaining determines which condition develops: near-total loss of function leads to Farber disease, while a partial deficiency (10–30% activity) results in SMA-PME — with a later onset and slower progression.
SMA-PME is frequently misdiagnosed — recognizing the symptoms early can change a child's life.
SMA-PME shares its molecular origin with Farber disease. Both stem from ASAH1 mutations and acid ceramidase deficiency — ASAH1 mutations typically reduce enzyme levels to below 30% of normal function, causing ceramides to accumulate in the body's lysosomes (cellular waste disposal compartments). Only a few dozen SMA-PME cases have been reported worldwide; Farber disease has approximately 200 documented cases. The primary barrier to research remains funding scarcity — medical research prioritizes conditions affecting larger populations.
Currently, no FDA-approved cure exists. Treatment options include anti-inflammatory medications, physical therapy, seizure management, and in some cases bone marrow or stem cell transplants — but none halt the underlying disease progression.
Many SMA-PME cases are initially misdiagnosed as Juvenile Myoclonic Epilepsy (JME). If a child is not responding to standard JME treatment, or presents with a combination of the symptoms below, please reach out to our team immediately. Early detection can improve quality of life.
Recognize the signs
Does your child show multiple of these symptoms? SMA-PME is frequently misdiagnosed as JME. Early contact can change everything.
Contact us for guidance →Some useful links
Nonprofit dedicated to accelerating research toward a cure for Farber disease — funding stem-cell gene therapy studies and raising awareness among families and medical professionals.
Visit Fight Farber
French association founded in 2019 by the parents of Calixte, diagnosed with SMA-PME. Their mission: raise awareness, connect affected families worldwide, and fund gene therapy research for ASAH1 mutations.
Visit ASAP for ChildrenSearch the NIH database for information on SMA-PME research and clinical trials
Search NIHNIH Genetic and Rare Diseases Information Center entry for SMA-PME Syndrome
View on GARD1 Journal of Biological Chemistry, Volume 271, Issue 51, pp. 32483–33156.